Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study.

Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, Bjornsson ES.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2601-10. Epub 2012 Mar 23.

PMID:
22441775
2.

Exon size distribution and the origin of introns.

Gudlaugsdottir S, Boswell DR, Wood GR, Ma J.

Genetica. 2007 Nov;131(3):299-306. Epub 2007 Feb 6.

PMID:
17279432
3.

BRCA2 mutation carriers, reproductive factors and breast cancer risk.

Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S, Thorlacius S, Jonasson JG, Tulinius H, Eyfjord JE.

Breast Cancer Res. 2003;5(5):R121-8. Epub 2003 Jun 24.

4.

Hypertension is frequently present in patients with reflux esophagitis or Barrett's esophagus but not in those with non-ulcer dyspepsia.

Gudlaugsdottir S, Verschuren W, Dees J, Stijnen T, Wilson J.

Eur J Intern Med. 2002 Sep;13(6):369.

PMID:
12225781
5.

The effect of a single BRCA2 mutation on cancer in Iceland.

Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugsdottir S, Eyfjord JE.

J Med Genet. 2002 Jul;39(7):457-62.

6.

Modelling errors in scoring the darkness of staining.

Hutchinson TP, Gudlaugsdottir S.

Anal Quant Cytol Histol. 2002 Apr;24(2):121-4. Review.

PMID:
12026050
7.

Prolonged use of proton pump inhibitors, CagA status, and the outcome of Helicobacter pylori gastritis.

Gudlaugsdottir S, van Dekken H, Stijnen T, Wilson JH.

J Clin Gastroenterol. 2002 May-Jun;34(5):536-40.

PMID:
11960065
8.

Modeling bivariate ordinal contingency tables arising in studies of interobserver variation, with application to cervical screening.

Hutchinson TP, Gudlaugsdottir S.

J Clin Epidemiol. 2002 Apr;55(4):422-3. No abstract available.

PMID:
11927213
9.

A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance.

Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH.

Eur J Gastroenterol Hepatol. 2001 Jun;13(6):639-45.

PMID:
11434588
10.

P53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations.

Gudlaugsdottir S, Sigurdardottir V, Snorradottir M, Jonasson JG, Ogmundsdottir H, Eyfjord JE.

Diagn Cytopathol. 2000 May;22(5):268-74.

PMID:
10790231
11.

Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium.

Laake K, Launonen V, Niederacher D, Gudlaugsdottir S, Seitz S, Rio P, Champème MH, Bièche I, Birnbaum D, White G, Sztan M, Sever N, Plummer S, Osorio A, Broeks A, Huusko P, Spurr N, Borg A, Cleton-Jansen AM, van't Veer L, Benitez J, Casey G, Peterlin B, Olah E, Børresen-Dale AL, et al.

Genes Chromosomes Cancer. 1999 Jul;25(3):212-21.

PMID:
10379867
12.

BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability.

Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarsdottir M, Jonasson JG, Anamthawat-Jonsson K, Eyfjörd JE.

Cancer Res. 1998 Mar 1;58(5):859-62.

13.

[DNA flow cytometry is a useful prognostic guide in the treatment of breast cancer.].

Gudlaugsdottir S, Sigurdsson H, Agnarsson BA, Jonasson JG, Kristjansdottir S, Baldursson G, Bjornsson S, Sveinsson T, Egilsson V.

Laeknabladid. 1996 Feb;82(2):138-47. Icelandic.

PMID:
20065406
14.

Altered expression of CA-125 in breast carcinomas.

Ogmundsdottir HM, Gudlaugsdóttir S, Björnsson J, Jonasdóttir S.

APMIS. 1996 Jan;104(1):47-53.

PMID:
8645458

Supplemental Content

Loading ...
Support Center